Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology and central nervous system (CNS) therapies, today announced the ...

Sanction covers use of drug to increase bone mass in patients with prostate or breast cancer undergoing hormone ablation therapy. FDA has approved two new indications for Amgen’s Prolia® (denosumab) ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius announced today that its operating company Fresenius Kabi, has introduced two new biosimilars - Conexxence ® (denosumab-bnht) and Bomyntra ® ...

The FINANCIAL — Amgen on October 9 announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Prolia (denosumab) for ...

Amgen and UCB are co-developing EVENITY. About Prolia® (denosumab) Prolia ® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of ...

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or ...

Fresenius Kabi’s fifth and sixth biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) have launched in the United States for all approved indications. Conexxence is approved for use ...

Please provide your email address to receive an email when new articles are posted on . Denosumab as a first-line osteoporosis therapy is linked to lower fracture risks than alendronate among ...

Recommendations on use of the new dual-action anabolic agent romosozumab (Evenity, Amgen) and how to safely transition between osteoporosis agents are two of the issues addressed in the latest ...

Doctors' opinions about whether to treat women with osteoporosis with hormone therapy vary. Guidelines by medical societies including those of the American College of Physicians, on the other hand, ...